What the FDA labels say about taking them together
Ixazomib and phenytoin
Ixazomib's FDA label of August 11, 2026 names phenytoin in its drug interactions section; the phenytoin labels PlainMeds reads (2) do not name ixazomib. The ixazomib label: “Avoid concomitant administration of NINLARO with strong CYP3A inducers.”
Check it at the source: the ixazomib FDA label on DailyMed (effective August 11, 2026, Takeda Pharmaceuticals America, Inc.); the phenytoin FDA label on DailyMed (effective October 15, 2024, Mylan Pharmaceuticals Inc.).
What does the ixazomib label say about phenytoin?
Ixazomib label, drug interactionsAvoid concomitant administration of NINLARO with strong CYP3A inducers (such as rifampin, phenytoin, carbamazepine, and St. John's Wort) [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (NINLARO), Takeda Pharmaceuticals America, Inc., effective August 11, 2026 (SPL set 038f2461-834b-4488-9ebd-863c83eef5a7), via openFDA; the full label on DailyMed
What does the phenytoin label say about ixazomib?
Phenytoin's label (effective October 15, 2024) and its 1 other brand-application label do not name ixazomib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Phenytek), Mylan Pharmaceuticals Inc., effective October 15, 2024 (SPL set 0f94c791-8b07-4b41-927e-c9f28bec5f60), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ixazomib | Phenytoin | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Seizures and epilepsy |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.145 per capsule 100 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once